Myriad Genetics, Inc. (MYGN)
Stock Price Chart
Key Info
| Market Cap | 997.54M |
| Revenue (ttm) | 760.80M |
| Net Income (ttm) | -199.50M |
| Shares Out | 74.55M |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | 12.64 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 13, 2020 |
| Last Price | $13.38 |
| Previous Close | $13.07 |
| Change ($) | 0.31 |
| Change (%) | 2.37% |
| Day's Open | 13.04 |
| Day's Range | 12.67 - 13.48 |
| Day's Volume | 881,499 |
| 52-Week Range | 9.24 - 47.10 |
More Stats
| Market Cap | 997.54M |
| Enterprise Value | 1.07B |
| Earnings Date (est) | Nov 10, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 74.55M |
| Float | 65.48M |
| EPS (basic) | -2.69 |
| EPS (diluted) | -2.01 |
| FCF / Share | 0.68 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 5.06% |
| Payout Ratio | n/a |
| Shares Short | 10.93M |
| Short Ratio | 13.10 |
| Short % of Float | 30.75% |
| Beta | 1.29 |
| PE Ratio | n/a |
| Forward PE | 12.64 |
| P/FCF Ratio | 19.75 |
| PS Ratio | 1.31 |
| PB Ratio | 0.96 |
| Revenue | 760.80M |
| Operating Income | -234.50M |
| Net Income | -199.50M |
| Free Cash Flow | 50.50M |
| Net Cash | -77.00M |
| Net Cash / Share | -1.03 |
| Gross Margin | 85.45% |
| Operating Margin | -30.82% |
| Profit Margin | -31.20% |
| FCF Margin | 6.64% |
| ROA | -2.43% |
| ROE | -14.49% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Hold
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 851 | 744 | 729 | 741 | 723 | 778 | 613 | 496 | 402 | 363 |
| Revenue Growth | 14.44% | 2.06% | -1.59% | 2.41% | -7.08% | 26.91% | 23.63% | 23.36% | 10.87% | - |
| Gross Profit | 650 | 567 | 558 | 583 | 576 | 669 | 534 | 431 | 355 | 318 |
| Operating Income | 8.70 | 60.70 | 43.20 | 153 | 134 | 274 | 228 | 180 | 158 | 135 |
| Net Income | 4.60 | 133 | 17.40 | 117 | 80.20 | 176 | 147 | 112 | 101 | 152 |
| Shares Outstanding | 73.50 | 69.40 | 68.30 | 70.00 | 71.30 | 75.70 | 80.90 | 84.61 | 89.79 | 96.34 |
| Earnings Per Share | 0.06 | 1.85 | 0.25 | 1.60 | 1.08 | 2.25 | 1.77 | 1.30 | 1.10 | 1.54 |
| EPS Growth | -96.76% | 640% | -84.38% | 48.15% | -52% | 27.12% | 36.15% | 18.18% | -28.57% | - |
| Operating Cash Flow | 83.70 | 116 | 106 | 166 | 141 | 190 | 174 | 142 | 131 | 155 |
| Capital Expenditures | -8.60 | -8.40 | -6.10 | -5.00 | -23.90 | -14.30 | -11.40 | -9.41 | -3.79 | -7.60 |
| Free Cash Flow | 75.10 | 108 | 100 | 161 | 117 | 176 | 163 | 132 | 127 | 147 |
| Cash & Equivalents | 137 | 181 | 151 | 159 | 145 | 186 | 372 | 341 | 346 | 403 |
| Total Debt | 234 | 9.30 | 99.10 | - | - | - | - | - | - | - |
| Net Cash / Debt | -96.60 | 171 | 51.60 | 159 | 145 | 186 | 372 | 341 | 346 | 403 |
| Assets | 1,563 | 1,175 | 1,209 | 881 | 766 | 824 | 804 | 691 | 611 | 594 |
| Liabilities | 474 | 209 | 441 | 132 | 104 | 105 | 75.23 | 54.98 | 44.04 | 36.27 |
| Book Value | 1,089 | 966 | 768 | 748 | 662 | 719 | 729 | 636 | 567 | 558 |
Company Profile
Company Details
| Full Name | Myriad Genetics, Inc. |
| Country | United States |
| Employees | 2,600 |
| CEO | R. Bryan Riggsbee |
Stock Information
| Ticker Symbol | MYGN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: MYGN |
| IPO Date | October 5, 1995 |
Description
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.